Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Charles Schwab Investment Management Inc. cut its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 7.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 526,045 shares of the company’s stock after selling 43,140 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.98% of Fulcrum Therapeutics worth $2,472,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. State Street Corp lifted its stake in shares of Fulcrum Therapeutics by 61.4% during the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after buying an additional 638,955 shares in the last quarter. Barclays PLC boosted its stake in shares of Fulcrum Therapeutics by 367.1% during the third quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after purchasing an additional 97,565 shares during the period. Braidwell LP bought a new position in Fulcrum Therapeutics in the third quarter worth approximately $3,817,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth approximately $474,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Fulcrum Therapeutics during the third quarter valued at about $721,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $3.01 on Friday. The firm has a market capitalization of $162.48 million, a price-to-earnings ratio of -9.71 and a beta of 2.20. The business’s 50 day moving average price is $3.53 and its 200-day moving average price is $3.76. Fulcrum Therapeutics, Inc. has a 1 year low of $2.78 and a 1 year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.63.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.